Promoting freedom, innovation, and growth

Connect with IPI

Receive news, research, and updates

Health Care

August 4, 2014

So Do We Need Pharmaceutical Innovation, or Not?

Today in the Wall Street Journal, there is good op/ed about the threat of Ebola and other infectious diseases that urges us to invest more money in medical innovation.

There's also another op/ed complaining that cutting edge, innovative medical cures are too expensive, and that we need something apparently just short of price controls to do something about it.

So which is it? Do we want pharmaceutical and biotech companies taking risks and innovating new cures, such as Sovaldi, the new cure for hepatitis? Or not?

Ms. Ignagni's piece is particularly egregious. It's part of a campaign that she's behind to get the federal government to forceably lower the price of Sovaldi, a blockbuster new miracle cure for hepatitis C. Note the word "cure."

First, she writes as if concern over high drug prices is a recent phenomenon, which of course it isn't. I've been hearing statists complaining about high drug prices for the 20 years I've been doing public policy. In fact, the first paper I ever edited and published at IPI was on this very topic. The redistributionists have never understood why they can't have all their diseases cured and their pain alleviated without it costing anyone anything. They're always focused on the second order concern--how goods are distributed--without fully appreciating the first order concern--how goods come to be in the first place.

Distributing existing goods is easy--innovating a new product or service that never existed before, now that's impressive. But apparently not to Ms. Ignagni. Read More >>

Posted by Tom Giovanetti | Comments

August 21, 2013

ObamaCare Creates Some More Part-Timers

I was talking with a lady, who is probably in her late 50s, when she told me she was going to start looking for a different job. See, she’s a teller working in the branch of one of the country’s largest banks, and the bank is making some cutbacks, turning its full-time tellers into part-timers (at some branches anyway).

I asked the next question, but I was pretty sure I already knew the answer: How many hours was the bank willing to let her work? Under 30, she said, which just so happens to be ObamaCare’s dividing line between those who must be covered with employer-provided health insurance and those who don’t. Read More >>

Posted by Merrill Matthews | Comments

May 30, 2013

A Way Around the Law

Health and Human Services Secretary Kathleen Sebelius has taken a lot of heat for asking--some would say shaking down--health insurance executives for money to help implement ObamaCare. So it has changed the messenger, but not the message. Read More >>

Posted by Merrill Matthews | Comments

January 8, 2013

mHealth Moving Along

The 2013 AT&T Developer Summit is underway in Las Vegas today. One of the many sessions hosted by AT&T, which are aimed at developers who are developing products, apps mainly, for use on their platform, was about mHealth, a sub-part of health technology.

Mobile health is an exciting area for many reasons but not the least is the huge potential for better outcomes for patients and opportunities for industry. Read More >>

Posted by Bartlett D. Cleland | Comments

July 11, 2012

Cato says Obamacare IPAB is Unconstitutional

Posted by Tom Giovanetti | Comments

June 13, 2012

"We will either find a way or make one."

Posted by Barry M. Aarons | Comments

May 24, 2012

Why Mess with the Success of PDUFA?

At a time when Congress can find very few issues on which there is widespread bipartisan support, it is important to act quickly and decisively when it does. One of those issues is currently before the Senate, the Food and Drug Administration Safety and Innovation Act, or FDASIA (S. 3187), a reauthorization and update of the Prescription Drug User Fee Act, or PDUFA. Read More >>

Posted by Merrill Matthews | Comments


Total Records: 22


IP Matters



  • TaxBytes-New

Copyright Institute for Policy Innovation 2018. All Rights Reserved Privacy Policy Contact IPI.

e-resources e-resources